Collegium Pharmaceutical Announces FDA Approval Of AllerNaze™, A Nasal Inhaled Steroid For The Treatment Of Allergic Rhinitis

Collegium Pharmaceutical Announces FDA Approval Of AllerNaze™, A Nasal Inhaled Steroid For The Treatment Of Allergic Rhinitis
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve (12) years of age and older.